Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
The purpose of this research study is to evaluate what type of treatment will be
beneficial for people with Crohn's disease and difficult to treat inflammation in the
small bowel. Current therapies are used to control the inflammation due to Crohn's
disease in your d...
Age: 18 - 80 years
Gender: All
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your dige...
Age: 18 - 80 years
Gender: All
Treatment of Moderate to Severe Refractory Crohn's Disease
This research study is testing an investigational research product called TRX103 as a
possible treatment for individuals suffering from Crohn's Disease (CD). The primary
purpose of this study is to learn how safe and effective different doses of TRX103 are
when admin...
Age: 18 - 65 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
Behavioral Therapy for Crohn's Disease
People living with Crohn's disease (CD) experience psychological and emotional symptoms,
in addition to known chronic and disabling physical symptoms, which prevent them from
living their life to the fullest (flourishing). Depression and anxiety are experienced by
30...
Age: 18 - 65 years
Gender: All
Behavioral Therapy for Crohn's Disease
People living with Crohn's disease (CD) experience psychological and emotional symptoms,
in addition to known chronic and disabling physical symptoms, which prevent them from
living their life to the fullest (flourishing). Depression and anxiety are experienced by
30...
Age: 18 - 65 years
Gender: All
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most often affecting the bowels. It can cause many
different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This
stud...
Age: 2 - 17 years
Gender: All
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most often affecting the bowels. It can cause many
different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This
stud...
Age: 2 - 17 years
Gender: All
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any
part of the gut. The purpose of this study is to evaluate the efficacy and safety of
TAK-279 versus placebo in participants with moderately to severely active Crohn's disease
(C...
Age: 18 - 75 years
Gender: All
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any
part of the gut. The purpose of this study is to evaluate the efficacy and safety of
TAK-279 versus placebo in participants with moderately to severely active Crohn's disease
(C...
Age: 18 - 75 years
Gender: All
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
The PLANET Study aims to determine the impact of microplastics on intestinal inflammation
and gut microbiome in order to understand the role of this pollutant on the risk of
developing inflammatory bowel disease (IBD) as well as other diseases. With this
information,...
Age: 18 years - 66+
Gender: All
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
The PLANET Study aims to determine the impact of microplastics on intestinal inflammation
and gut microbiome in order to understand the role of this pollutant on the risk of
developing inflammatory bowel disease (IBD) as well as other diseases. With this
information,...
Age: 18 years - 66+
Gender: All
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with
or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess
the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with
...
Age: 2 - 17 years
Gender: All
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with
or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess
the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with
...
Age: 2 - 17 years
Gender: All
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of
guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance
therapy (Week 52) among participants who were in clinical response to guselkumab at Week
12.
Age: 2 - 17 years
Gender: All
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of
guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance
therapy (Week 52) among participants who were in clinical response to guselkumab at Week
12.
Age: 2 - 17 years
Gender: All
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to
receive mirikizumab or another intervention. The purpose of the mirikizumab study is to
evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body
of p...
Age: 2 - 17 years
Gender: All
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to
receive mirikizumab or another intervention. The purpose of the mirikizumab study is to
evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body
of p...
Age: 2 - 17 years
Gender: All
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
The purpose of this study is to evaluate the efficacy, safety, drug levels, and drug
effects of ozanimod in pediatric participants with moderately to severely active Crohn's
Disease.
Age: 2 - 17 years
Gender: All